Nohla Names Noonberg Chief Medical Officer, Delaney Shifts to CSO

Nohla Therapeutics has hired Sarah Noonberg to serve as its chief medical officer. She takes the place of Nohla founder Colleen Delaney, who is now the Seattle biotech’s chief scientific officer. Noonberg most recently worked at Prothena (NASDAQ: [[ticker:PRTA]]), where she was chief medical officer. Her experience also includes positions at BioMarin Pharmaceutical (NASDAQ: [[ticker:BMRN]]) and Medivation. Nohla’s lead therapeutic candidate, dilanubicel, was developed to temporarily restore bone marrow function in cord blood transplant patients, as well as those receiving high doses of chemotherapy. The experimental treatment is currently in Phase 2 studies.

Author: Frank Vinluan

Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times. View all posts by Frank Vinluan